OPHTHALMOLOGY
Alexion is investigating the potential role of complement inhibition in treating distinct and severe ophthalmic disorders, including age-related macular degeneration, or AMD, a disease that gradually destroys central vision.
AMD has two forms: dry AMD and wet AMD. Dry AMD causes blurred central vision, which can gradually worsen over time. Dry AMD also can progress to wet AMD, an advanced form of the disease in which abnormal blood vessels leak blood and fluid. Loss of central vision can occur quickly with wet AMD.1
An investigator-initiated Phase 2 proof-of-concept study is evaluating an intravenous formulation of eculizumab as a potential treatment for dry AMD. Alexion also is evaluating its broad portfolio of preclinical complement system regulators, including TT30 and TA106, for potential use in the treatment of AMD and other severe ophthalmic disorders. By pursuing multiple mechanisms within the complement system, the company’s objective is to develop the optimal form of complement inhibition for local ophthalmic use.
References
- “Facts About Age-Related Macular Degeneration.” National Eye Institute. National Institutes of Health. Available at: http://www.nei.nih.gov/health/maculardegen/armd_facts.asp. Accessed February 3, 2011.